Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

AIM: Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) and insulin combination therapy is an effective treatment option for type 2 diabetes, but long‐term data are lacking. The aim was to assess the long‐term efficacy of the GLP‐1RA liraglutide in subgroups by insulin use in the LEADER trial. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Tack, Cees J., Jacob, Stephan, Desouza, Cyrus, Bain, Stephen C., Buse, John B., Nauck, Michael A., Petrie, John R., Poulter, Neil R., Pratley, Richard E., Stegmann, Helen Vanya B. K., Bosch‐Traberg, Heidrun, Startseva, Elena, Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852575/
https://www.ncbi.nlm.nih.gov/pubmed/31282028
http://dx.doi.org/10.1111/dom.13826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852575/
https://www.ncbi.nlm.nih.gov/pubmed/31282028
http://dx.doi.org/10.1111/dom.13826

Ejemplares similares